Cardio-oncology & otherResearch article
Biomarkers for Cardiovascular Drug Development
- Narrative review
Main finding
As reported in the abstract
Context-of-use framework for circulating biomarkers in CV drug development
- Biomarkers assessed along 2 converging evidence lanes: analytical readiness and clinical or statistical validation
- Frequent discordance between biological plausibility or prognostic strength and treatment-induced changes that reliably predict clinical benefit (eg, albuminuria, natriuretic peptides, glycemic, inflammatory and lipid markers)
- Only a few biomarkers materially shape trial design or regulatory decisions; still fewer meet stringent criteria for surrogate endpoints
Original publication
Biomarkers for Cardiovascular Drug Development. J Am Coll Cardiol. Published 11 February 2026. doi:10.1016/j.jacc.2025.12.072
Summarised from the published abstract; every number is checked against it